It is also noteworthy that metabolic dysfunction in CD8+ T cells, driven by the immunosuppressive microenvironment of chronic lymphocytic leukaemia (CLL), contributes to CAR-T therapy resistance (Van Bruggen et al, 2019). The gene discussed is CD8A; the disease is B-cell chronic lymphocytic leukemia.